Century Therapeutics, Inc.

Listed Company

IPSCCIK 0001850119NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31

Period

FY 2025

Revenue

$109.16M

Net Income

$-9.60M

Total Assets

$223.70M

Equity

$158.94M

Shares Out

179.72M

Op. Cash Flow

$-103.90M

Business

Century Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic, iPSC-derived cell therapies for autoimmune diseases and cancer. It develops engineered immune effector products including CAR‑iNK and CAR‑iT cell candidates (e.g., CNTY‑101, CNTY‑308, CNTY‑341) using CRISPR-mediated edits, proprietary Allo‑Evasion™ technology, and protein engineering. Its activities span clinical development, preclinical pipeline prioritization, and in‑house and partnered manufacturing capabilities. The company conducts clinical trials in the United States and Europe and distributes investigational products via clinical sites, collaborations, and contractual manufacturing partners.

Summary from filing dated 2025-03-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	109	7	2	5	—
Research and development	96	107	93	97	76
General and administrative	24	33	35	32	19
Impairment of long-lived assets	7	—	—	—	—
Impairment of goodwill	—	4	—	—	—
Total operating expenses	126	145	149	139	95
Loss from operations	−17	−138	−147	−134	−95
Interest income	7	13	13	—	—
Other income	275,000	354,000	−383,000	3	−898,000
Total other income	8	13	12	3	—
Loss before provision for income taxes	−10	−125	−135	−131	−96
(Benefit) provision for income taxes	−68,000	2	−2	−91,000	−43,000
Net loss	−10	−127	−137	−131	−96
Net loss per common share Basic (in dollars per share)	−0.14	−1.61	−2.3	−2.27	−2.96
Net loss per common share Diluted (in dollars per share)	−0.14	−1.61	−2.3	−2.96	−2.96
Weighted average common shares outstanding Basic (in shares)	87	79	59	58	32
Weighted average common shares outstanding Diluted (in shares)	87	79	59	32	32
Unrealized gain (loss) on investments	−294,000	153,000	3	−2	−615,000
Foreign currency translation gain	—	63,000	−32,000	−26,000	−32,000
Comprehensive loss	−10	−126	−134	−133	−96

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-03-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash and cash equivalents	62	58	—	47	84
Short-term investments	55	131	—	125	231
Prepaid expenses and other current assets	4	5	—	4	4
Total current assets	121	194	—	177	320
Property and equipment, net	50	62	—	72	83
Operating lease right-of-use assets	16	29	—	20	29
Restricted cash	2	3	—	2	2
Long-term investments	—	31	—	89	52
Intangible assets	34	34	—	—	—
Security deposits and non-current assets	211,000	528,000	—	541,000	1
Total assets	224	353	—	361	487
Accounts payable	5	3	—	3	5
Accrued expenses and other liabilities	12	17	—	10	10
Contingent consideration liability, short-term	4	—	—	—	—
Deposit liability	20,000	82,000	—	584,000	866,000
Deferred revenue, current	—	109	—	4	7
Total current liabilities	20	130	—	18	30
Operating lease liability, long term	40	49	—	47	39
Contingent consideration liability, long-term	—	9	10	—	—
Deferred tax liability	4	4	—	—	—
Total liabilities	65	192	—	176	184
Commitments and contingencies (Note 9)	—	—	—	—	—
Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized and 0 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	—	—	—	—	—
Common stock, $0.0001 par value, 300,000,000 shares authorized; and 87,519,096 and 85,836,429 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	9,000	9,000	—	6,000	6,000
Additional paid-in capital	951	943	—	840	824
Accumulated deficit	−792	−782	—	−656	−519
Accumulated other comprehensive income	30,000	324,000	—	108,000	−2
Total stockholders' equity	159	161	—	185	303
Total liabilities and stockholders' equity	224	353	—	361	487

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−10	−127	−137	−131	−96
Depreciation	13	13	13	8	4
Non-cash operating lease expense (benefit)	2	−271,000	−1	2	834,000
Stock based compensation	7	13	15	11	5
Impairment	7	4	—	—	—
Accretion of investments	−2	−5	−4	—	—
Change in fair value of contingent liabilities	−5	−1	—	—	—
Gain on reduction in lease liability due to lease termination	−1	959,000	—	—	—
Deferred tax (benefit) expense	−73,000	870,000	—	—	—
Prepaid expenses and other assets	2	543,000	667,000	1	−3
Operating lease liability	−5	−3	14	5	−41,000
Deferred revenue	−109	−7	−2	118	—
Accounts payable	2	−1	−2	−5	−2
Accrued expenses and other liabilities	−4	2	−730,000	4	1
Net cash used in operating activities	−104	−110	−88	14	−89
Acquisition of property and equipment	−848,000	−154,000	−14	−31	−45
Acquisition of fixed maturity securities, available for sale	−51	−120	−209	−254	−330
Sale of fixed maturity securities, available for sale	160	177	284	271	77
Acquisition of Clade Therapeutics, Inc., net of cash acquired	—	−10	—	—	—
Net cash provided by investing activities	108	47	61	−13	−298
Proceeds from issuance of common stock and ESPP	173,000	141,000	516,000	345,000	213,000
Proceeds from ATM, net of issuance costs	—	18	—	—	—
Proceeds from PIPE, net of issuance costs	—	57	—	—	—
Net cash provided by financing activities	173,000	75	−10	27	418
Net increase in cash, cash equivalents, and restricted cash	4	12	−37	28	30
Reduction of ROU asset and lease liability due to non-cash lease modification	4	—	—	—	—
Cash paid for income tax	4	501,000	3	—	14,000
Issuance of Equity to satisfy contingent liability	447,000	—	—	—	—
Stock issued in connection with the Acquisition	—	15	—	—	—
Landlord paid leasehold improvements	—	934,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro